

**AMENDMENTS TO THE CLAIMS:**

Please amend the claims as follows:

Claims 1-15. (Cancelled)

16. (Currently Amended) A pharmaceutical composition comprising a lipid extract obtained by extraction from the mother of pearl from mother-of-pearl molluscs, and further comprising a pharmaceutically acceptable support.

17. (Previously Presented) The composition according to claim 16, wherein the mother-of-pearl molluscs are oysters.

18. (Previously Presented) The composition according to claim 17, wherein oysters are oysters of the genus Pinctada and more particularly of the genus Pinctada species margaritifera.

19. (Previously Presented) The composition according to claim 16, wherein the pharmaceutically acceptable support is an excipient suitable for topical, enteral or parenteral application.

20. (Previously Presented) The composition according to claim 16, wherein the pharmaceutically acceptable support is an excipient suitable for topical application.

21. (Previously Presented) The composition according to claim 16, wherein the lipids are present at a concentration comprised between 0.02% and 3% by weight, preferably between 0.25% and 2% by weight, and advantageously between 0.5% and 1%, relative to the total weight of the composition.

22. (Previously Presented) The composition according to claim 16, for the treatment of pathologies involving a decrease in filaggrin activity and/or an increase in membrane transglutaminase activity.

23. (Previously Presented) The composition according to claim 16, for the treatment of pathologies related to a decrease in cutaneous filaggrin activity and/or cutaneous overexpression of membrane transglutaminase.

24. (Previously Presented) The composition according to claim 16, for the treatment of cutaneous pathologies, more particularly selected in the group consisting of psoriasis, ichthyosis and atopic dermatitis.

25. (Previously Presented) The composition according to claim 16, for the treatment of autoimmune diseases related to an autoimmune reaction to filaggrin, in particular rheumatoid arthritis.

26. (Previously Presented) The composition according to claim 16, wherein it further comprises at least one other therapeutically active ingredient for use that is simultaneous, separate or spread out over time.

27. (Previously Presented) The composition according to claim 17, wherein the other therapeutically active ingredient is selected from corticosteroids, coal tar, anthralin, vitamin D3 and derivatives, and retinoids.

28. (Currently Amended) A device, wherein said device comprises the lipid extract ~~comprising lipids~~ such as defined in claim 16 and a physiologically acceptable excipient.

29. (Previously Presented) The device according to claim 28, having a form which is suitable to subcutaneous or percutaneous injection, in particular in the form of a syringe or infusion.